Heidelberg Pharma AG reaffirmed earnings guidance for 2021. The Heidelberg Pharma Group confirms its full-year financial guidance issued on 25 March 2021. The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 5.5 million and EUR 7.5 million in sales revenue and other income (2020: EUR 9.6 million) for the 2021 fiscal year. Loss before interest and taxes (EBIT) for 2021 are expected to be between EUR 30.0 million and EUR 34.0 million.